表紙
市場調査レポート

Atacicept(全身性エリテマトーデス・ループス腎炎):予測と市場分析

Atacicept (Systemic Lupus Erythematosus and Lupus Nephritis) - Forecast and Market Analysis to 2022

発行 GlobalData 商品コード 290507
出版日 ページ情報 英文 61 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.12円で換算しております。
Back to Top
Atacicept(全身性エリテマトーデス・ループス腎炎):予測と市場分析 Atacicept (Systemic Lupus Erythematosus and Lupus Nephritis) - Forecast and Market Analysis to 2022
出版日: 2013年10月31日 ページ情報: 英文 61 Pages
概要

当レポートでは、自己免疫疾患(AID)の潜在的な治療薬として開発中の、Ataciceptについて調査分析し、全身性エリテマトーデス(SLE)・ループス腎炎(LN)の概要と治療ガイドライン、競合情勢、製品情報、主要国の売上予測、売上情報などを提供して、概略以下の構成でお届けいたします。

第1章 目次

第2章 イントロダクション

第3章 疾病の概要

  • 病因・病態生理
    • 病因
    • 病態生理
  • 予後
  • 生活の質(QOL)
  • 症状

第4章 疾病の管理

  • 診断の概要
    • SLEの診断
    • LNの診断
  • 治療の概要

第5章 競合評価

  • 概要
  • 戦略的競合企業の評価

第6章 機会とアンメットニーズ

  • 概要
  • アンメットニーズ
  • 機会

第7章 パイプライン評価

  • 概要
  • 臨床開発中の有望な薬剤

第8章 Atacicept

  • 概要
  • 効能
  • 安全性
  • 投与・処方
  • 潜在的な臨床的位置付け
  • 潜在的な商業的位置付け
  • 価格と償還
  • SWOT分析
  • 予測

第9章 付録

図表

目次
Product Code: GDHC277DFR

Systemic lupus erythematosus (SLE) is a systemic inflammatory autoimmune disease that can affect any organ or tissue and is the prototypic autoimmune disease. While SLE can affect multiple major organ systems in the body, one of its most severe manifestations includes renal (kidney) involvement, known as lupus nephritis (LN). The term LN refers to SLE patients with glomerulonephritis, and when the term LN is used, glomerular tissue injury in the kidneys is always involved. Renal injury without any glomerular involvement is classified as nephritis in a patient with SLE.

Merck Serono is developing atacicept, under license from ZymoGenetics (now Bristol-Myers Squibb), for the potential treatment of autoimmune diseases, including SLE. Atacicept is a fusion protein of the extracellular portion of the transmembrane activator and CAML interactor (TACI) receptor and the Fc portion of human immunoglobulin G (IgG) and is being developed as a subcutaneous formulation.

Scope

  • Overview of SLE-LN, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Atacicept including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Atacicept for the top seven countries from 2012 to 2022.
  • Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for SLE-LN
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Atacicept performance
  • Obtain sales forecast for Atacicept from 2012-2022 in top seven countries (the US, France, Germany, Italy, Spain, the UK and Japan)

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Prognosis
  • 3.3. Quality of Life
  • 3.4. Symptoms

4. Disease Management

  • 4.1. Diagnosis Overview
    • 4.1.1. SLE Diagnosis
    • 4.1.2. LN Diagnosis
  • 4.2. Treatment Overview

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Strategic Competitor Assessment

6. Opportunity and Unmet Need

  • 6.1. Overview
  • 6.2. Unmet Needs
    • 6.2.1. Efficacious Treatments with Reduced Side Effects
    • 6.2.2. Management of LN
    • 6.2.3. Improvement in Patients' Mortality
    • 6.2.4. Management of Lupus Comorbidities
    • 6.2.5. Sensitive and Reliable Biomarkers
    • 6.2.6. Physicians' Education and Public Awareness of SLE
    • 6.2.7. Unmet Needs Gap Analysis
  • 6.3. Opportunities
    • 6.3.1. Efficacious and Safe Therapies
    • 6.3.2. Therapies Targeting LN Patients
    • 6.3.3. Treatments for Common Lupus Comorbidities
    • 6.3.4. Discovery of Biomarkers

7. Pipeline Assessment

  • 7.1. Overview
  • 7.2. Promising Drugs in Clinical Development

8. Atacicept

  • 8.1. Overview
  • 8.2. Efficacy
  • 8.3. Safety
  • 8.4. Dosing and Formulation
  • 8.5. Potential Clinical Positioning
  • 8.6. Potential Commercial Positioning
  • 8.7. Pricing and Reimbursement
  • 8.8. SWOT Analysis
  • 8.9. Forecast

9. Appendix

  • 9.1. Bibliography
  • 9.2. Abbreviations
  • 9.3. Methodology
  • 9.4. Forecasting Methodology
    • 9.4.1. Diagnosed SLE and LN Patients
    • 9.4.2. Percent Drug-Treated Patients
    • 9.4.3. General Pricing Assumptions
    • 9.4.4. Generic Erosion
    • 9.4.5. Pricing of Pipeline Agents
  • 9.5. Physicians and Specialists Included in this Study
  • 9.6. Primary Research - Prescriber Survey
  • 9.7. About the Authors
    • 9.7.1. Analysts
    • 9.7.2. Global Head of Healthcare
  • 9.8. About GlobalData
  • 9.9. Disclaimer

List of Tables

  • Table 1: Symptoms of SLE
  • Table 2: 1997 Updated ACR Criteria for Classification of SLE
  • Table 3: The SLICC Clinical and Immunologic Criteria for Classification of SLE
  • Table 4: WHO and ISN/RPS classifications of LN
  • Table 5: Treatment Guidelines for SLE and LN
  • Table 6: Most Prescribed Drugs for SLE and LN by Class in the Global Markets, 2013
  • Table 7: Leading Treatments for SLE and LN, 2013
  • Table 8: Overall Unmet Needs in SLE and LN - Current Level of Attainment
  • Table 9: Clinical Unmet Needs in SLE and LN - Gap Analysis, 2013
  • Table 10: SLE and LN - Phase Pipeline, 2013
  • Table 11: Comparison of Therapeutic Classes in Development for SLE and LN, 2013
  • Table 12: Product Profile - Atacicept
  • Table 13: Atacicept SWOT Analysis, 2013
  • Table 14: Global SLE Sales Forecasts ($m) for Atacicept, 2012-2022
  • Table 15: Global LN Sales Forecasts ($m) for Atacicept, 2012-2022
  • Table 16: Number of Physicians Surveyed by Country

List of Figures

  • Figure 1: Overview of the Etiology and Pathogenesis of SLE
  • Figure 2: Overview of the BAFF/APRIL Ligand and Receptor System
  • Figure 3: Overview of the Treatment Management of SLE
  • Figure 4: Competitive Assessment of Late-Stage Pipeline Agents in SLE and LN, 2012-2022
Back to Top